- Molecular NameEtomidate
- SynonymEtomidic acid
- Weight244.294
- Drugbank_IDDB00292
- ACS_NO33125-97-2
- Show 3D model
- LogP (experiment)3.05
- LogP (predicted, AB/LogP v2.0)2.49
- pka4.2
- LogD (pH=7, predicted)2.49
- Solubility (experiment)0.0632 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.42
- LogSw (predicted, AB/LogsW2.0)0.23
- Sw (mg/ml) (predicted, ACD/Labs)0.93
- No.of HBond Donors0
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA44.12
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyA short acting intravenous anaesthetic agent used for the induction of general anaesthesia and for sedation for short procedures such as reduction of dislocated joints and cardioversion.
- Absorption_valueN/A
- Absorption (description)Rapidly distributed after intravenous injection.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding75.0
- Volume of distribution (VD)4 to 5 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:whole blood ratio, 0.62.
- MetabollsmIt is metabolised in the liver by hydrolysis and N-dealkylation to inactive metabolites.
- Half life5 h
- ExcretionAbout 90% of a dose is excreted in the urine as the carboxylic acid derivative, together with mandelic acid and benzoic acid; less than 5% is excreted as unchanged drug.
- Urinary ExcretionN/A
- Clerance9~18 ml/min/kg
- ToxicityUndesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
- LD50 (rat)LD50=35 (intravenous)
- LD50 (mouse)LD50=45